Log In
Print
BCIQ
Print
Print this Print this
 

SelG1

  Manage Alerts
Collapse Summary General Information
Company Selexys Pharmaceuticals Corp.
DescriptionHumanized mAb against P selectin (SELP; CD62P)
Molecular Target P selectin (SELP) (CD62P)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationSickle cell disease
Indication DetailsPrevent or reduce sickle cell-related pain crises; Treat sickle cell disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$665.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today